NASDAQ:FDMT

4d Molecular Therapeutics Stock Predictions

Healthcare > Biotechnology

Buy FDMT

*Your capital is at risk

$11.30

-1.01 (-8.20%)

At Close: Jul 13, 2026

Currently predicting for Wed, 15 Jul 2026

FDMT Live board

Community Bull/Bear

Target Next close

Join the FDMT prediction battle

Create a free account to see the full board, submit your call, compare with other predictors, and build a public record.

Create free account Log in

FDMT Prediction Chart

Unlock the prediction chart

Registered users can inspect target prices, community averages, and how calls develop across recent sessions.

Create free account Log in

Forecast Desk

3-Month Forecasts For FDMT

Forecasts map a 66-session price path from approved predictors. Log in or create a free account to view forecasts and request one for this ticker.

Create free account Log in to view forecasts

FDMT Predictions History

Predictor	Target Session	Target Price	Accuracy
Community predictor	Next session	USD target	Record locked
Ranked predictor	Previous session	Bullish/Bearish	Score locked

See the prediction record

Create free account Log in

Forecast Desk

Request A 3-Month Forecast

Price path
Approved predictor
3-month horizon

Create Free Account Log In To View Forecasts

ABOUT 4D MOLECULAR THERAPEUTICS, INC.

4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; ...

Read Full Profile Here

GOLDEN STAR

Ticker	Change	Signal Date
SRPT $17.02	10.58%	Jun 29
NMRK $15.02	0.466%	Jun 24
X XMAX $8.34	2.40%	Jun 24
NESR $25.07	12.49%	Jun 23
CAG $13.43	6.70%	Jun 23

Unlock

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by